Search Clinical Trials
Terminated
Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP (External Link)
Prior to any bone marrow transplant, we will need patients to: - Answer questions about their medical history; - Undergo a physical examination; - Have tests done to see how …
Baylor Role:
Collaborator
Terminated
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO (External Link)
To be treated on this study, we will test the blood to check for viruses, including HIV (the virus that causes AIDS). If the HIV test is positive, a transplant …
Baylor Role:
Lead Sponsor
Terminated
LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL) (External Link)
Investigators first tested a biopsy of the tumor that has already been done to see if the tumor cells are EBV positive. They then got permission to take up to …
Baylor Role:
Lead Sponsor
Terminated
Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients (External Link)
Initial studies in renal and recent studies in adult cardiac transplant patients have shown Zenapax(R) to be both efficacious and safe when used in several different dosing schedules. Little data …
Baylor Role:
Lead Sponsor
Terminated
Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases (External Link)
Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) …
Baylor Role:
Lead Sponsor
Terminated
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT (External Link)
Patients will have received a haplo-identical stem cell transplant on our on-going study "CD45 (YTH-24 and YTH-54) and CD52 (Campath 1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell …
Baylor Role:
Lead Sponsor
Terminated
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia (External Link)
Before patients receive any treatments, they will have the following: - Complete history and physical exam - Dental consultation - Bone marrow aspirate - Blood tests - Urinanalysis - Tests …
Baylor Role:
Lead Sponsor
Terminated
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (External Link)
We expect that the patient's participation in this study will last approximately 18 months to 2 years. Before treatment begins, they will be evaluated to confirm they meet the requirements …
Baylor Role:
Lead Sponsor
Terminated
Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia (External Link)
If clinically feasible (no aplasia, no active malignancy), the recipients marrow will be harvested and cryopreserved as a back up for use if non-engraftment/rejection is followed by failure to undergo …
Baylor Role:
Lead Sponsor
Terminated
Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H (External Link)
Study participants will receive the following treatment: Day -5 to -2...Fludarabine 30mg/m2* and CAMPATH** 1H 10mg IV Day -1.........Day of rest Day 0..........Stem cell transplant (infusion) Where possible, patients will …
Baylor Role:
Lead Sponsor